Redeye considers AAC’s Q4 report to be soft, with revenues below its revised full-year guidance, pri...
Waystream Group reported a strong Q4, with sales increasing 60% y-o-y and gross margin remaining sol...
* NOI +8.2% y-o-y, +4.0% vs ABGSCe, +0.9% vs cons. * Value changes of +0.
Redeye updates on EG7 after Q4-results which were stronger than expected, while the company also cle...
Redeye briefly comments on Initiator Pharma’s announcement that the EPO has granted a European paten...
Redeye updates its forecasts following Modelon’s Q4 2025 report, which highlighted a year of success...
Redeye is optimistic after Medivir's Q4 report. The new programme in osteogenesis imperfecta holds s...
Redeye provides an update following Senzime’s Q4 2025 report.
Redeye retains its positive view of Avensia despite lowering our Base Case and forecasts.
Q4 was weaker than expected due to a softer topline, which we partially attribute to a temporary bli...
Redeye comments on the new Nevisense data in atopic dermatitis (AD).
Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was init...
Q4 a bump in the road but we remain optimistic on outlook* Estimates down given a lower AUM base * 2...
Redeye comments on Avensia’s Q4 report, showing softer margins than expected.
Redeye gives a short initial take on today’s Q4 report from BioArctic.
Redeye provides an initial take following Senzime’s Q4 2025 report.
BICO's Q4 report aligned closely with our projections and does not prompt any meaningful change to o...
Given that Thunderful’s shares will soon be delisted, the quarterly result is not important for shar...
* Good underlying growth, investing for the future weighs on margin * DTC could accelerate in 2026 *...
Redeye updates on Hacksaw after Q4-results which saw somewhat stronger-than-expected profitability w...
